TY - JOUR
T1 - Prevention of oral and salivary gland impairment in irradiated adolescent patients with head and neck cancer
T2 - A suggested protocol
AU - Davidovich, Esti
AU - Peretz, Benjamin
AU - Aframian, Doron J.
PY - 2007/3
Y1 - 2007/3
N2 - Patients with head and neck cancer receive high doses of localized irradiation therapy, which results in destruction of salivary gland secretion ability. Pilocarpine hydrochloride was shown to have some beneficial effect on quality of life of these patients. Most studies concentrated on adult patients with head and neck cancer with no reference to adolescents. This case report demonstrates the long-term beneficial effect of pilocarpine hydrochloride in maintaining sufficient saliva, oral soft tissue integrity, and caries-free status in an adolescent cancer patient who received a total radiation dose of 6,000 cGy. A suggested protocol for management of irradiated adolescent patients with head and neck cancer is offered.
AB - Patients with head and neck cancer receive high doses of localized irradiation therapy, which results in destruction of salivary gland secretion ability. Pilocarpine hydrochloride was shown to have some beneficial effect on quality of life of these patients. Most studies concentrated on adult patients with head and neck cancer with no reference to adolescents. This case report demonstrates the long-term beneficial effect of pilocarpine hydrochloride in maintaining sufficient saliva, oral soft tissue integrity, and caries-free status in an adolescent cancer patient who received a total radiation dose of 6,000 cGy. A suggested protocol for management of irradiated adolescent patients with head and neck cancer is offered.
KW - Adolescent
KW - Head and neck radiation
KW - Pilocarpine hydrochloride
KW - Salivary function
KW - Salivary glands
UR - http://www.scopus.com/inward/record.url?scp=33846991999&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 17334001
AN - SCOPUS:33846991999
SN - 0033-6572
VL - 38
SP - 235
EP - 239
JO - Quintessence International
JF - Quintessence International
IS - 3
ER -